Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment

M. Cortellaro, T. Nencioni, C. Boschetti, S. Ortolani, F. Buzzi, B. Francucci, M. P. Caraceni, P. Abelli, F. Polvani, C. Zanussi

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient. Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors. Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.

Original languageEnglish
Pages (from-to)555-559
Number of pages5
JournalEuropean Journal of Clinical Pharmacology
Volume41
Issue number6
DOIs
Publication statusPublished - Dec 1991

Fingerprint

Menopause
Estradiol
Serum
Therapeutics
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Blood Coagulation Factors
Follicular Phase
Endometrium
Parathyroid Hormone
LDL Cholesterol
Phosphorus
Triglycerides
Cholesterol
Calcium
Lipids
Pharmaceutical Preparations

Keywords

  • acetate
  • adverse effects
  • conjugated oestrogens
  • medroxyprogesterone
  • menopause - oestradiol
  • plasma lipids
  • postmenopausal women
  • transdermal delivery

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Cyclic hormonal replacement therapy after the menopause : Transdermal versus oral treatment. / Cortellaro, M.; Nencioni, T.; Boschetti, C.; Ortolani, S.; Buzzi, F.; Francucci, B.; Caraceni, M. P.; Abelli, P.; Polvani, F.; Zanussi, C.

In: European Journal of Clinical Pharmacology, Vol. 41, No. 6, 12.1991, p. 555-559.

Research output: Contribution to journalArticle

Cortellaro, M, Nencioni, T, Boschetti, C, Ortolani, S, Buzzi, F, Francucci, B, Caraceni, MP, Abelli, P, Polvani, F & Zanussi, C 1991, 'Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment', European Journal of Clinical Pharmacology, vol. 41, no. 6, pp. 555-559. https://doi.org/10.1007/BF00314984
Cortellaro, M. ; Nencioni, T. ; Boschetti, C. ; Ortolani, S. ; Buzzi, F. ; Francucci, B. ; Caraceni, M. P. ; Abelli, P. ; Polvani, F. ; Zanussi, C. / Cyclic hormonal replacement therapy after the menopause : Transdermal versus oral treatment. In: European Journal of Clinical Pharmacology. 1991 ; Vol. 41, No. 6. pp. 555-559.
@article{f821b68e6adb4e89898e9589a5a9cbac,
title = "Cyclic hormonal replacement therapy after the menopause: Transdermal versus oral treatment",
abstract = "In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient. Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors. Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.",
keywords = "acetate, adverse effects, conjugated oestrogens, medroxyprogesterone, menopause - oestradiol, plasma lipids, postmenopausal women, transdermal delivery",
author = "M. Cortellaro and T. Nencioni and C. Boschetti and S. Ortolani and F. Buzzi and B. Francucci and Caraceni, {M. P.} and P. Abelli and F. Polvani and C. Zanussi",
year = "1991",
month = "12",
doi = "10.1007/BF00314984",
language = "English",
volume = "41",
pages = "555--559",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Cyclic hormonal replacement therapy after the menopause

T2 - Transdermal versus oral treatment

AU - Cortellaro, M.

AU - Nencioni, T.

AU - Boschetti, C.

AU - Ortolani, S.

AU - Buzzi, F.

AU - Francucci, B.

AU - Caraceni, M. P.

AU - Abelli, P.

AU - Polvani, F.

AU - Zanussi, C.

PY - 1991/12

Y1 - 1991/12

N2 - In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient. Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors. Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.

AB - In an open, randomized, comparative, between-patient trial, 45 postmenopausal women were treated for 4 months with cyclical transdermal oestradiol 0.05 mg per day or oral conjugated equine oestrogens 0.625 mg per day, in both cases, plus, medroxyprogesterone acetate 10 mg per day on the last 8 days of each cycle. Similar relief from postmenopausal symptoms was obtained with both treatments. Post-treatment histological evaluation of the endometrium did not reveal neoplastic or hyperplastic change in any patient. Early follicular-phase plasma oestradiol levels were observed only after transdermal oestradiol. There was a significant reduction in serum total cholesterol and LDL cholesterol in both treatment groups, with no difference between treatments, whereas serum triglyceride levels were decreased only by transdermal oestradiol. Plasma calcium and phosphorus fell significantly and serum intact parathyroid hormone rose significantly, with no difference between the therapies. No significant changes were observed in clotting factors. Transdermal oestradiol appears to be an effective and safe hormonal replacement therapy, and this route of administration may be responsible for the more useful action of the drug on serum lipids and plasma oestradiol levels.

KW - acetate

KW - adverse effects

KW - conjugated oestrogens

KW - medroxyprogesterone

KW - menopause - oestradiol

KW - plasma lipids

KW - postmenopausal women

KW - transdermal delivery

UR - http://www.scopus.com/inward/record.url?scp=0025932242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025932242&partnerID=8YFLogxK

U2 - 10.1007/BF00314984

DO - 10.1007/BF00314984

M3 - Article

C2 - 1667755

AN - SCOPUS:0025932242

VL - 41

SP - 555

EP - 559

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -